Brief: Lantern Pharma Reports Fourth Quarter And Fiscal Year 2022 Financial Results And Operational Highlights
20/03/2023 20:02
March 20 (Reuters) - Lantern Pharma Inc LTRN.O :
* LANTERN PHARMA REPORTS FOURTH QUARTER AND FISCAL YEAR 2022
FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS
* $55.2 MILLION IN CASH, CASH EQUIVALENTS, AND MARKETABLE
SECURITIES AS OF DECEMBER 31, 2022
* LANTERN HAS A CASH RUNWAY INTO 2025.
* QTRLY LOSS PER SHARE $0.31
* Q4 EARNINGS PER SHARE VIEW $-0.47 -- REFINITIV IBES DATA
Source text for Eikon: ID:nBw10TVfka
Further company coverage: LTRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Receives Taiwan Approvals To Open Next Stage Of Phase 2 Harmonic Trial Of Lp-300 In Never-Smoker, Egfr-Mutant Nsclc
Brief: Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update
Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price
Lantern Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview